Janku, Filip <br/><br/>
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.  [electronic resource] 

 -  Cell reports  Jan 2014 
 - 377-87 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>2211-1247 
<br/><br/><label>Standard No.: </label>10.1016/j.celrep.2013.12.035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Class I Phosphatidylinositol 3-Kinases<br/>Colorectal Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Mutation<br/>Ovarian Neoplasms--drug therapy<br/>PTEN Phosphohydrolase--genetics<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors